Fig. 3: Comparative immunogenicity of mRNA-LNP vaccine candidates encoding three different versions of VZV gE antigen. | npj Vaccines

Fig. 3: Comparative immunogenicity of mRNA-LNP vaccine candidates encoding three different versions of VZV gE antigen.

From: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine

Fig. 3

Female C57BL/6 mice (5 animals per group) were primed with a full human dose of the live-attenuated VZV) vaccine (Varivax®) by subcutaneous administration. Mice were then injected intramuscularly with 1 or 5 μg of mRNA-LNP vaccine candidates, encoding the three gE variants, or saline (Varivax® only group) at 4 and 8 weeks post Varivax® administration. A Scheme of immunization and sample collection schedule. B Longitudinal Log10 end-point titers (Y-axis) of gE-specific IgG binding antibodies detected in sera collected from mice at the indicated timepoints and evaluated by ELISA. Arrows indicate mRNA-LNP/Shingrix® immunization time points. Data shown as Mean ± SEM. C Quantitative assessment of anti-gE serum IgG binding antibodies in mice from all vaccinated groups at 12 weeks post Varivax® prime, assessed by ELISA and expressed as area under the curve (AUC) (Y-axis) based on absorbance values. Data shown as Mean ± SEM.

Back to article page